Meeting
2022 ASCO Annual Meeting
Personalized neoantigen DNA vaccines expand tumor-specific T cells in the periphery which infiltrate the tumor in hepatocellular carcinoma.
Authors
Renzo Perales
Geneos Therapeutics, Plymouth Meeting, PA
Renzo Perales , Mark Yarchoan , Neil Cooch , Niranjan Sardesai , Alfredo Perales-Puchalt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2638)
DOI
10.1200/JCO.2022.40.16_suppl.2638
Abstract #
2638
Poster Bd #
293
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Personalized DNA neoantigen vaccine in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma.
First Author: Mark Yarchoan
Poster
2023 ASCO Annual Meeting
Effect of personalized immunization with GNOS-PV02 of patients with hepatocellular carcinoma on TCR clonal expansion, tumor infiltration, and vaccine-specific reactivity.
First Author: Renzo Perales
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2023 ASCO Annual Meeting
Immune infiltrates in metastatic uveal melanoma liver metastases and associations with clinical outcomes.
First Author: Katherine Emilie Rhoades Smith